Not only hubs but overall, approximately more than 30% percent of upregulated kinases in primary and recurrent GBM samples showed potential to be modified by SUMO2/3 via mass-spectrometry based analysis (Additional file 5: Figure S3A and Additional file 4: Table S13). This evidence concerns the gene SUMO2 and glioblastoma.